Overview

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if a novel 4-drug anti-HIV combination can suppress the growth of HIV in patients infected with the virus.
Phase:
Phase 2
Details
Lead Sponsor:
Abbott
Treatments:
Efavirenz
Lamivudine
Lopinavir
Ritonavir
Tenofovir